Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharma leader advancing CRISPR-engineered allogeneic CAR-T cell therapies. This page aggregates official announcements, clinical trial milestones, and strategic developments related to its chRDNA technology platform.
Investors and researchers will find timely updates on Caribou's innovative pipeline programs targeting hematologic cancers and autoimmune diseases. Key focus areas include CB-010 for B-cell malignancies, CB-011 in multiple myeloma, and autoimmune applications of PD-1 knockout therapies.
The repository features press releases on clinical trial data, regulatory progress, intellectual property developments, and strategic collaborations. Content is organized to highlight scientific advancements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Caribou's latest CRISPR innovations and corporate announcements. Check regularly for updates on allogeneic cell therapy developments and their potential impact on treatment paradigms.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing company, announced its upcoming participation in key events. On June 2, 2024, the company will host a webcast at 7:00 pm CDT, discussing CB-010 ANTLER Phase 1 trial data in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) from the 2024 ASCO Annual Meeting. The presentation will include insights from notable figures in hematology and oncology. Additionally, Caribou will present at the Jefferies Global Healthcare Conference on June 5, 2024, and participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. Webcasts for these events will be available on the Caribou website for 30 days.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will participate in upcoming investor conferences, including the 2024 RBC Capital Markets Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The company will present at these events, offering webcasts for more information.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
